New combo aims to make resistant prostate cancer cells visible to targeted radiation

NCT ID NCT06145633

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 28 times

Summary

This study tests whether the drug vorinostat can help men with a type of advanced prostate cancer that has low levels of a specific marker (PSMA). The marker is needed for a radioactive therapy called 177Lu-PSMA-617 to work. By giving vorinostat first, the hope is to increase PSMA levels so the radiation can better attack the cancer. About 15 men with PSMA-low metastatic castration-resistant prostate cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

CASTRATION-RESISTANT PROSTATE CARCINOMA METASTATIC PROSTATE ADENOCARCINOMA STAGE IVB PROSTATE CANCER AJCC V8 STAGE IVB PROSTATE CANCER AJCC V8